Corporate | 11 April 2006 10:40
STRATEC plans to issue bonus shares
Corporate-news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
STRATEC plans to issue bonus shares
Birkenfeld, April 11, 2006
The Supervisory Board and Board of Management of STRATEC Biomedical Systems
AG, which is listed in the Prime Standard, have decided to propose the
execution of a capital increase from company funds and the issuing of bonus
shares for approval by the Annual General Meeting on June 23, 2006.
The share capital is to be increased in this respect by converting
reserves. In the course of this measure, each shareholder is to receive two
new shares (bonus shares) for each existing share. No deposit is to be made
by the shareholders. By undertaking the capital increase from company
funds, STRATEC would like to make its share more attractive for investors
and facilitate trading with the share.
Should the Annual General Meeting of STRATEC Biomedical Systems AG provide
its consent, then following the execution of this measure the volume of
STRATEC shares held by shareholders in their securities accounts will
automatically treble. This measure has no impact on the volume of
shareholders’ equity at the company; it will merely result in a regrouping
within the components of shareholders’ equity. Overall, the share capital,
which currently amounts to EUR 3,678,345.00, will increase to EUR
11,035,035.00, divided into 11,035,035 individual ordinary bearer shares in
the company with a nominal value of EUR 1.00 each.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories and research
institutes around the world. The company develops its products on the basis
of its own patented technologies. Shares in the company (SIN: 728900 /
ISIN: DE0007289001) are traded in the Prime Standard segment of the
Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart
Stock Exchange and on other exchanges.
The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical
Systems AG’, as well as the subsidiaries ‘STRATEC NewGen’, ‘Robion’ and
‘Sanguin’.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de
(c)DGAP 11.04.2006
—————————————————————————
language: English
emitter: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
phone: +49 (0)7082 7916 0
fax: +49 (0)7082 7916 999
email: info@stratec-biomedical.de
WWW: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
indexes:
stockmarkets: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin-Bremen, München, Hamburg, Düsseldorf
End of News DGAP News-Service
—————————————————————————